Exicure Inc (XCUR)

[LocWolf]

Tata boy....come to daddy, drop down to .50 and say you are sorry for that past RS...then, perhaps I will forgive you and buy more shares.

[LocWolf]

Take it down to .50 cent than it might be worth a handful of my change...I can still feel the blisters from that 1/30 RS months ago. It is amazing someone didn't end up in jail referencing past management.

[subslover]

Thanks for the reply. I know very little about this Company except for the fact that it is lightly traded. I hate when management keeps shareholders in the dark. They are due to file their 10k and I'm sure it is ugly.
Now I'm not saying that something big can happen here but with the noninterest of investors, I have to pass..

[LocWolf]

I don't know what to think about this except is it possible some private company and Exicure will reverse merge. No way in heck will this (in my opinion) be able to maintain Nasdaq listing unless some type of merger is in the works. I gather the share structure is perfect or setup for this to possibly happen because we are too damn far away to rise high enough in the time span we need before any real (dream) of a product.

I hated the RS we went through and will look at the math in my account as to what share price this needs to fall to make it possible for me to reinvest but with the past fiasco involving past CEO David.... I'm incline to just let what shares I have left sit and hope and poke and not buy in again. At my age I ll probably be gone before I see anything to be excited about like we did in the past.

Sure is a damn shame this up and coming corporations to end up in a crappy fiasco and lose at least 50 institutional investments/investors so be very cautious in jumping back into this and besides the maintenance/lease on our 30,000 sq ft building is going to take a bite out of us. You probably can hear your voice echo on that floor especially losing no less than 50% of their employees but believe that percentage has risen since.

Under the past fiasco I don't think lawsuits were strong enough several should have been arrested and dealt with.

[subslover]

On December 15, 2022, the Company held a Special Meeting of Stockholders (the “Special Meeting”), at which a quorum was present. At the Special Meeting, the stockholders of the Company voted on the following two proposals: (1) to approve the issuance of 3,400,000 newly issued shares of common stock of the Company (“Common Stock”) by the Company to CBI USA, Inc. (“CBI USA”) in a private placement at a price per share of $1.60 (the “Private Placement”), which would result in a “change of control” of the Company under the applicable rules of Nasdaq (“Proposal 1”), and (2) to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposal (“Proposal 2”). The final results of the voting on each proposal are set forth below.

[LocWolf]

Grab your socks again looks like crap may hit the wall again? https://www.sec.gov/ix?doc=/Archives/edgar/data/1698530/000169853022000064/xcur-20220822.htm

[subslover]

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

[nunaka]

Useless POF ticker will be back under a buck in nothing flat.

[LocWolf]

Of course like I said prior XCUR is doing a RS but I find it so strange that they didn't determine the reverse split structure in an exactly ratio prior to voting. At any rate those who might be interested....... https://www.sec.gov/ix?doc=/Archives/edgar/data/1698530/000169853022000037/xcur-20220610.htm

[kzivann]

Will this bounce around the low? Watch.

XCUR

[Triple nickle]

AH. Their trying so hard to keep it from running up. Don’t think they have the shares they post to do it

[Triple nickle]

Closed this on an upswing

[nunaka]

Any input on the post (#267) previous to yours regarding the annual meeting, reverse split, etc.? I am confused...

[Triple nickle]

XCUR

[Triple nickle]

Added a boat load

[Timing101]

XCUR, here it comes , large insider buying! see here
https://seekingalpha.com/news/3841307-exicure-up-25-pre-market-following-insider-buy

[1984ISHERE]

REVERSE SPLIT COMING HERE

https://www.sec.gov/Archives/edgar/data/1698530/000110465922041485/tm2210605-2_pre14a.htm

[PennyPusher786]

Lost all gains in 4 hours

[PennyPusher786]

Yes you're right. Perhaps people are pulling out of the market, Shorts going hard with that downward momentum.

[MacBoys]

Yes but the previous weeks I’ve had some success. This week just been getting burned hard core

[PennyPusher786]

I would say much longer than Week

[MacBoys]

This play right here sums up how this entire week has been going in the market

[PennyPusher786]

Not even a slim chance of a reversal in sight... You'd think it would've found a bottom by now, but then it tanks even further lol...

[PennyPusher786]

What a pathetic run. Lol cut short at market open

[kingsransome]

more buys vs sells today $$$$

[LocWolf]

Reverse split coming May 27th "1 for every 10" or as much as "1 for every 30" shares.

[kingsransome]

lete see that .25 pivy $$$$

[LocWolf]

Exicure AS is 200 million shares and the OS shares are 123 million shares but the "fully diluted" shares are only 89 million what the hell. They should have increased the Authorized Shares. Sure the problem with de-listing to the OTC may have happen in June but what I am seeing is Exicure (as I said prior) absolutely nothing to offer investors to stay. The fully diluted shares are only 89 million so if they are so trigger happy at that figure what are we going to see in the future. We had at one time 149 Institutional Investments in this company and last check a few days ago I believe it was 65 and most likely less by now. They may be able to increase their share price by reversing but again with only 89 million share fully diluted this really sucks big time.

I gather legal actions (because Exicure) has also cost us.

[LocWolf]

This sucks....Exicure Proxy 1-10 or 1-30 RS, To be voted on May 27, 2022 at 2:00pm Eastern time.

https://www.sec.gov/Archives/edgar/data/1698530/000110465922041485/tm2210605-2_pre14a.htm

[adamski]

In a report released today, Keay Nakae from Chardan Capital reiterated a Hold rating on Exicure (XCUR – Research Report), with a price target of $0.25. The company's shares closed last Monday at $0.20, close to its 52-week low of $0.14. According to TipRanks.com, Nakae is a 4-star analyst with an average return of 11.8% and a 43.0% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Mountain Crest Acquisition II, and Arrowhead Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Exicure.

[oneforone]

Exicure Shares Plunge After Q4 Results Included A Going Concern Risk

[LocWolf]

Normally we would be de-listed on June 28th 2022 but even though management has changed plus our troubles I'm sure we will stay on the Nasadq without de-listing threat until late December 2022 at which time we would be receive notice of de-listing if XCUR hasn't kissed $1 dollar closing share price for 10 business days.

I wonder if any traders are thinking of buying this Monday at rock bottom price and then on June 28, 2022 seeing if Exicure doesn't need the NASDAQ extension because it kissed $1 dollar share price for 10 business days. I would not risk that play as I feel Exicure will file the necessary paperwork and get that 180 day extension (if needed) on June 28th 2022....not bad could mean .80 per share gain in less than 90 days provided we reached $1.00 share price.

[LocWolf]

It is a continuation of their 2017 employee incentive program with basically registering 4,900,000 shares that were worth .31 cent per share on March 25th 2022.


Here is just the reporting by "Cooley LLP"
https://www.sec.gov/Archives/edgar/data/1698530/000169853022000022/ex51_cooleyopinionfors-8maa.htm


Below is the main S-8 if you wish to read it.
https://www.sec.gov/Archives/edgar/data/1698530/000169853022000022/exicure-formsx8march2022.htm

[lakerol]

What does THE S-8 say, didnt Read thru it yet?

[lakerol]

What does THE S-8 say, didnt Read thru it yet?

[LocWolf]

4 pm close basically .26 cent. Now check out the after hours trades over 6 million shares traded and we dropped to .16 and closed around 8pm with brain damage at .19 cent per share.

The S-8 is also embarrassing if you were he when our share price was around $3.25 or so.

[nunaka]

Although it dipped to .18 after hours, its interesting that Ihub has XCUR @ .19 while every one else, including my broker, has it @ .26, the price at the close of the regular trading session.

[LocWolf]

I am very wrong about that...I just read the entire 10-K

On December 10, 2021, the Company announced its commitment to a plan to wind down the Company’s immuno-oncology program for cavrotolimod (AST-008) and the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia. The Company intends to realign its research and development resources to support (i) the development of its preclinical program targeting SCN9A for neuropathic pain, (ii) the continued advancement of its partnered programs with Ipsen Biopharm Limited to develop SNA-based treatments in neuroscience targeting Huntington’s disease and Angelman syndrome, (iii) its continued advancement of its partnered program with AbbVie to develop SNA-based treatments for hair loss disorders, as well as (iv) the continued research and development of other undisclosed therapeutic product candidates.

[lakerol]

What do you mean, plus about Abbvie too?
You know They paid off all dept last week of 7 Mill out of 40 Mill cash balance. Smallcaps Never do this, specially when running low in cash later in 2022.

[LocWolf]

So the .31 cents yesterday was referencing the S-8 filed a couple hours ago. I don't think we can even maintain .31 but we shall see?

[LocWolf]

Ok, I see exactly what happened within Exicure and that actually couldn't be much worse because it involved David who has been behind this company and Northwest University for many many years. This also means that we have no chance in getting Chad Mirkin on board again in the next 100 years. Many of our patents evolve around David and Chad plus the Integrity of NW University. I bought this with and average of $1.44 per share and seriously I will not be buying any more XCUR stock. When I talked about this dropping to .10 cent per share well! it will drop even lower. What a damn shame I mean even Bill Gates bought into this years ago at around $5 -$7 per share since one of his close buddies got involved here. I can't believe that David twisted things around accordingly.

Please be aware before investing money in Exicure.


https://mirkin-group.northwestern.edu/people/chad-mirkin/

[LocWolf]

On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Messrs. Giljohann and Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned Puri v. Giljohann, et al., Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned Sim v. Giljohann, et al., Case No. 1:22-cv-01217. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri and Sim complaints (the “Derivative Complaints”) allege that the defendants caused the Company to issue false and/or misleading statements in its 2021 proxy statement regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties owed under state law. The Derivative Complaints also assert that Messrs. Giljohann and Bock are liable for contribution under the federal securities laws. The Puri complaint further asserts state law claims for unjust enrichment, abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seeks restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company’s shareholders.
We may also be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

[LocWolf]

Sorry I missed the 10-k as I didn't see it soon enough.........

https://www.sec.gov/ix?doc=/Archives/edgar/data/1698530/000169853022000019/xcur-20211231.htm

Off hand NOW up to 123 million OS

Item 3. Legal Proceedings.
On December 13, 2021, Mark Colwell filed a putative securities class action lawsuit against the Company, David A. Giljohann and Brian C. Bock in the United States District Court for the Northern District of Illinois, captioned Colwell v. Exicure, Inc. et al., Case No. 1:21-cv-0663. On February 4, 2021, Plaintiff filed an amended putative securities class action complaint. The amended complaint alleges that Messrs. Giljohann and Bock made materially false and/or misleading statements related to the Company’s clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The amended complaint does not quantify any alleged damages but, in addition to attorneys’ fees and costs, plaintiff seeks to recover damages on behalf of himself and others who acquired the Company’s stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. On February 11, 2022, four members of the putative class moved the Court for appointment as lead plaintiff in the action pursuant to the Private Securities Litigation Reform Act of 1995. Two of those motions were withdrawn on February 25, 2022, and two remain pending. On February 16, 2022, the Court entered an order stating that defendants need not answer, or otherwise respond, until the Court enters an order appointing lead plaintiff and lead counsel, and the parties then submit a schedule to the Court for the filing of a further amended complaint and the timing of defendants’ answer or response.
84

[LocWolf]

Here is the 8-k for you.........

https://www.sec.gov/Archives/edgar/data/1698530/000169853022000017/a8kq42021exhibit991.htm

Yes pretty much what I was expecting and dreading. I would state again I see us rocking back to under the teens. It will take a good while for us to make the gains in share price that we lost. It would seem to me that someone should be sued for the BS they created by not being honest.

Like I said trust will need to be earned and that make take a longtime...more than many of us have to wait this out.


Looks like they have gone from .28 cents loss per share to .78 cent loss per share. Boy this doesn't sound good plus about AbbVie too.

_______________________________________________

Anyone else have any thoughts about this?

[LocWolf]

I believe "if" Exicure files results it will be an 8-k on same day they file their yearly 10-k, due no later than the 31st of March.

Exicure has always filed their 10-k two to three weeks before the due date.

[kingsransome]

thought earnings were to be yesterday?

[LocWolf]

In some ways that is good and in others not so meaning we are a long ways from any deal which we need badly. We only have half staff and we must pay the lease on the building. I am surprised that our share3price moved upwards and feel it can't maintain or grow without another big deal. Look no doubt there trust is going to be a big issue moving forward. Our money will be made as the result of a revolutionary drug delivery system coupled with this amazing digital designing that can handle 3 separate types actions. If are not successful enough with what we presently have I don't see any new collaborations and that is what we need to shift gears and hire back our people and pack our institutional buyers and investment funds. I know we can't change what has happen but we need one such as Chad Mirkin to get involved again.

https://mirkin-group.northwestern.edu/people/chad-mirkin/

[adamski]

8k

Item 1.02 Termination of a Material Definitive Agreement

Termination of MidCap Credit Agreement

As previously disclosed, on September 25, 2020, Exicure, Inc. (“Exicure”) and Exicure Operating Company, Exicure’s wholly owned subsidiary (collectively with Exicure, the “Company”), entered into a Credit and Security Agreement (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “MidCap Credit Agreement”) with MidCap Financial Trust, as agent, and the lenders party thereto from time to time.

On March 15, 2022, the Company repaid in full all outstanding indebtedness and other obligations under the MidCap Credit Agreement and other Financing Documents (as defined in the MidCap Credit Agreement) and terminated all obligations thereunder (other than with respect to any obligations that are expressly specified to survive the termination).

[adamski]

Agree

[chemix97]

about to have an explosive run- bringing some ENGA profits into this bad boy. Short percentage down 85%, insider/fund buying at all time high